SCHEMBL13715344

SCHEMBL13715344

CCCc1c[nH]c2cccc(Cl)c12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 3/20 0.69
SLC6A4 P31645 1/20 0.66
HTR1A P08908 2/20 0.47
HTR2A P28223 9/20 0.46
HTR2C P28335 6/20 0.45
HTR2B P41595 5/20 0.45
HTR6 P50406 2/20 0.45
NR4A2 P43354 1/20 0.45
DRD1 P21728 1/20 0.45
HTR1D P28221 1/20 0.45
HTR1B P28222 1/20 0.45
HTR1E P28566 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
HTR7 P34969 1/20 0.45
DRD3 P35462 1/20 0.45
HTR5A P47898 1/20 0.45
FFAR1 O14842 1/20 0.42
DRD2 P14416 1/20 0.42
GPR17 Q13304 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19604558 0.86 GPR84 (0.73) GPR84SLC6A4HTR1AHTR2AHTR2C
SCHEMBL26285351 0.83 HTR1A (0.70) GPR84SLC6A4HTR1AHTR2AHTR2C
SCHEMBL4220443 0.83 GPR84 (0.69) GPR84SLC6A4HTR1AHTR2AHTR2C
SCHEMBL2533008 0.83 GPR84 (0.69) GPR84SLC6A4HTR1AHTR2AHTR2C
SCHEMBL11273551 0.83 GPR84 (0.69) GPR84SLC6A4HTR1AHTR2AHTR2C
SCHEMBL24243710 0.82 HTR2A (0.63) GPR84SLC6A4HTR1AHTR2AHTR2C
SCHEMBL8543544 0.82 SLC6A4 (0.83) GPR84SLC6A4HTR1AHTR2AHTR2C
SCHEMBL24243679 0.82 SLC6A4 (0.68) GPR84SLC6A4HTR1AHTR2AHTR2C
Hydrochloric Acid SCHEMBL21546036 0.81 GPR84 (0.67) GPR84SLC6A4HTR1AHTR2AHTR2C
SCHEMBL13715392 0.81 GPR84 (0.71) GPR84SLC6A4HTR1AHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465880-B1 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE TO TREAT DISORDERS ASSOCIATED WITH SOMATOSTATINE IPSEN PHARMA (FR) 2009-08-05 EP disclosed